India's ban on antimicrobial fixed-dose combinations: winning the battle, losing the war?

ABSTRACT:

Background and objectives

India, the country with the largest market availability of antimicrobial fixed-dose combinations (FDCs), banned certain antimicrobial FDCs in September 2018. Our objective was to examine the impact of Government ban on the sales of antimicrobial FDCs.

Methods

The sales patterns of 14 of the 26 banned antimicrobial FDCs were analyzed using monthly private sector drug sales data from IQVIA (a comprehensive and nationally representative drug sales database) between January 2018 and December 2019. We carried out descriptive analyses to evaluate the trend in sales over time for banned and non-banned antimicrobial FDCs using cumulative sales volumes.

Results

Overall, the cumulative sales volume of banned antimicrobial FDCs declined by 75% between J

SUBMITTER: Sulis G 

PROVIDER: S-EPMC9047325 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature